Novelty Nobility licenses c-Kit ADC candidate NN3201 to US biotech for $553m
In short
Novelty Nobility said it signed a global licensing deal on Sept 30 with a US biotech for its c-Kit-targeting antibody-drug conjugate candidate NN3201, worth $553 million (about 744.3 billion won). The partner gains worldwide exclusive development and commercialisation rights, while the counterparty and detailed terms, including the upfront payment, were not disclosed. Novelty Nobility will separately receive commercial milestones and royalties on sales after commercialisation.
Read the full story 1 min read
Novelty Nobility said on Oct 6 that it signed a global licensing contract on Sept 30 with a US biotech company for its antibody-drug conjugate cancer candidate NN3201, in a deal worth $553 million, or about 744.3 billion won. The company said the counterparty and detailed terms, including the upfront payment, would not be disclosed under an agreement between the two sides. [ 1 , 4 ]
Under the contract, the partner secures exclusive worldwide development and commercialisation rights to NN3201. Novelty Nobility said it will receive commercial milestones tied to sales and royalties separately after commercialisation. [ 1 , 4 ]
NN3201 targets c-Kit and is in a phase 1 basket trial in the United States in patients with solid tumours that overexpress the protein. According to the company, the candidate binds c-Kit outside the cell, unlike existing small-molecule c-Kit targeted therapies that act mainly on c-Kit inside the cell and can lose potency depending on the mutation; Novelty Nobility says NN3201 was designed to produce anticancer effects regardless of mutation type. [ 1 , 4 ]
The two companies plan to examine NN3201's potential in blood cancers, with acute myeloid leukaemia as the main development target, citing limited treatment options for patients who relapse after standard therapy or do not respond to it. Maeil Business reported the partner rated the blood-cancer potential highly based on data from the solid-tumour trial, according to the company. [ 1 , 4 ]
Novelty Nobility CEO Park Sang-gyu said the licensing contract is meaningful beyond a commercial result because it lays the basis for the company's continued growth, adding that it will work closely with the partner so that NN3201 can reach patients awaiting new treatment options. [ 1 , 4 ]
Why it matters
The deal is reported by Korean business outlets as a technology export by a domestic antibody developer to a US biotech, with the licence value disclosed in dollars as well as won. The documents say the partner acquires global rights to the candidate and that both sides plan to examine blood-cancer uses, so the drug's further development and any revenue will depend on an unidentified foreign company. The documents give no detail on upfront cash or the partner's identity, so the near-term financial effect on Novelty Nobility is not clear from this coverage.
Key facts
- Novelty Nobility said the global licensing contract for NN3201 was signed on Sept 30 and announced on Oct 6. [ 1 , 4 ]
- The contract is valued at $553 million, or about 744.3 billion won. [ 1 , 4 ]
- The partner company gains exclusive worldwide development and commercialisation rights to NN3201. [ 1 , 4 ]
- The counterparty and detailed terms, including the upfront payment, were not disclosed under an agreement between the two companies. [ 1 , 4 ]
- Novelty Nobility will separately receive commercial milestones tied to sales and royalties after commercialisation. [ 1 , 4 ]
- NN3201 is a c-Kit-targeting antibody-drug conjugate in a phase 1 basket trial in the United States in patients with solid tumours that overexpress c-Kit. [ 1 , 4 ]
- The companies plan to review NN3201 in blood cancers, with acute myeloid leukaemia as the main indication. [ 1 , 4 ]
- CEO Park Sang-gyu said the deal lays a basis for the company's continued growth and that it will work closely with the partner to bring NN3201 to patients. [ 1 , 4 ]
Confirmed by several sources
- Novelty Nobility signed a global licensing contract for NN3201 with a US biotech on Sept 30 and disclosed it on Oct 6. [ 1 , 4 ]
- The total contract value is $553 million, about 744.3 billion won. [ 1 , 4 ]
- The partner obtains exclusive global development and commercialisation rights to NN3201. [ 1 , 4 ]
- The partner's identity and detailed terms were not disclosed. [ 1 , 4 ]
Still unclear
- The name of the US biotech partner and the contract's detailed terms, including the upfront payment. Documents 1 and 4 state that the counterparty and details were not disclosed by agreement between the two companies, so only single-reporting of the deal's structure is available.
- Whether the US partner has confirmed the deal or issued its own statement. All documents report the transaction from Novelty Nobility's side; no document cites a statement from the partner.
- The location of Novelty Nobility and of the signing. No document names a city or place for the company or the contract.
What local media are saying
Timeline, local time
- Asia Economy publishes its report on the NN3201 licensing deal. [ 1 ]
- Korea Economic Daily publishes a report headlined on the 744.3 billion won technology transfer. [ 2 ]
- Newsis publishes a report that the ADC cancer drug candidate was licensed to a US company. [ 3 ]
- Maeil Business publishes its account of the $553 million licensing deal. [ 4 ]